Locally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) is the most common stage at diagnosis for this disease. Despite significant advancements in cure rates through surgery and chemoradiotherapy, recurrence rates remain high, underscoring the need for alternative strategies to improve outcomes. Immunotherapy, particularly PD-1 inhibitors, has become the standard of care in recurrent or metastatic settings, sparking interest in their use in LA-HNSCC. This review synthesizes the findings of clinical trials investigating neoadjuvant immunotherapy over the past five years, highlighting its potential to improve overall survival and prevent recurrence. We emphasize the substantial heterogeneity of these studies in terms of treatment regimens, combinations, and durations, which complicates the interpretation and comparison of results. Additionally, we discuss the potential role of immunotherapy in tailoring subsequent treatment strategies based on response. We also address key challenges in clinical trial design, such as the selection of appropriate endpoints (e.g., pathological response, toxicity, and time-to-event endpoints like disease-free survival or overall survival) and the integration of biomarkers to predict outcomes. Preliminary findings suggest that adding chemotherapy or other checkpoint inhibitors to PD-1 inhibitors may enhance pathological responses, although further research is needed to determine if this translates into longer survival and improved quality of life. We emphasize the need to identify predictive biomarkers for patient selection and establish consensus in trial design to facilitate result comparisons. In conclusion, while neoadjuvant immunotherapy offers promising opportunities, ongoing research is crucial to refine its clinical application and maximize its therapeutic potential in LA-HNSCC patients.
Immunotherapy has significantly improved the treatment of metastatic solid tumors; however, detecting early signs of response to enable timely intervention for resistant tumors remains challenging. A blood-only circulating tumor DNA (ctDNA) test may provide a rapid assessment of tumor response without reliance on matched tumor tissue. We applied a tissue-agnostic, genome-wide methylation enrichment assay, based on cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq), to plasma samples from patients in a phase 2 trial evaluating pembrolizumab across multiple solid tumors (NCT02644369). A decrease in ctDNA from baseline to pre-cycle 3 was significantly associated with higher objective response and clinical benefit rates and longer progression-free and overall survival in univariate analyses, with these associations remaining significant in multivariable models except for overall survival. These results validate a commercial-grade, tissue-agnostic plasma cfDNA methylation platform for immunotherapy response monitoring, which may facilitate earlier, more informed treatment decisions and improve patient outcomes.
Circulating tumor DNA (ctDNA) has many potential applications in the management of cancer, including detection, monitoring, and treatment response assessment. This study evaluates pre-treatment ctDNA detection in a single-institution pan-cancer cohort using a highly sensitive tumor-informed ctDNA assay. Participant samples were collected at the University Health Network across six study cohorts. A total of 273 patients with stage II-IV cancers spanning 16 tumor types were analyzed using a personalized tumor-informed assay (RaDaR®). Harmonized methods were employed to mitigate the impact of variables known to influence ctDNA detection and its quantification. Pre-treatment ctDNA was detected in 83% of participants (226/273) across all stages and cancer types. Detection rates varied by clinical characteristics, including cancer type and stage; ctDNA was detected in 100% of stage IV metastatic recurrent high-grade serous ovarian cancer (HGSOC) patients (n = 8/8) and 54% of stage IV melanoma patients (n = 6/11). The median estimated variant allele fraction (eVAF) across all patients with a positive ctDNA result was 0.25% (range: 0.000029–37.7%), varied by tumor type and increased with cancer stage. A total of 11% of positive samples (24/226) had an eVAF of <0.01%. This pan-cancer ctDNA analysis using a highly sensitive assay reveals high detection rates overall, including ~10% at low levels (<0.01% eVAF), offering a reference for future clinical ctDNA applications and furthering our understanding of factors influencing ctDNA measurements.
High-risk human papillomavirus (HPV)-related and most cases of HPV-negative locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC) have substantial risks of relapse despite definitive therapy, and thus represent conditions of unmet clinical need. The ability now exists to detect molecular residual disease (MRD) in these patients post-definitive treatment such as surgery or (chemo)radiotherapy using novel and highly sensitive and specific technologies to measure cancer-derived circulating biomarkers. The positive and negative predictive values of these assays to forecast cancer recurrence, as well as the lead time of circulating tumor DNA (ctDNA) detection before clinical relapse, are relevant as these parameters rationalize the design of clinical trials for cancer interception in the MRD setting. Currently, there is evidence that interception in the MRD setting yields benefit in clinical outcome in some cancers, but such data do not yet exist in LA-HNSCC and will require prospective testing via clinical trials.